Form 483

WES Pharma Inc. Form 483, 2018-12-13

FDA issued a Form 483 to WES Pharma Inc. on 2018-12-13 with 8 public-safe observations.

483· Form 483 issuedHuman Drugs8 observations

WES Pharma Inc. · Westminster, United States · Issued December 13, 2018

Overview

  • 8 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

13 Dec 2018
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Marcus A Ray

13 Dec 2018
21 CFR 211.42(c)(2)

Rejected Material Area

Cited by Marcus A Ray

13 Dec 2018
21 CFR 211.67(b)

Written procedures not established/followed

Cited by Marcus A Ray

13 Dec 2018
21 CFR 211.68(b)

Computer control of master formula records

Cited by Marcus A Ray

13 Dec 2018
21 CFR 211.68(b)

Computer control of master formula records

Cited by Marcus A Ray

Inspected site

WPWES Pharma Inc.Westminster, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.192Cited across public-safe Form 483 observations2x
21 CFR 211.42(c)(2)Cited across public-safe Form 483 observations2x
21 CFR 211.67(b)Cited across public-safe Form 483 observations2x
21 CFR 211.68(b)Cited across public-safe Form 483 observations2x

Full 483 report

Get the verbatim text of all 8 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere